Search details
1.
The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.
Pediatr Nephrol
; 36(4): 889-898, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33048203
2.
Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.
Pediatr Nephrol
; 36(4): 1033, 2021 Apr.
Article
in English
| MEDLINE | ID: mdl-33296010
3.
Identification of a Locus on the X Chromosome Linked to Familial Membranous Nephropathy.
Kidney Int Rep
; 6(6): 1669-1676, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-34169208
Results
1 -
3
de 3
1
Next >
>>